MedPath
HSA Product

SMOFlipid 20%

Product approved by Health Sciences Authority (SG)

Basic Information

SMOFlipid 20%

INJECTION, EMULSION

Regulatory Information

SIN13246P

April 12, 2007

General Sale List

Therapeutic

INTRAVENOUS

August 10, 2023

June 3, 2025

XB05BA02

Company Information

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Active Ingredients

Soybean oil

Strength: 60g per 1000ml

Medium chain triglycerides

Strength: 60g per 1000ml

Purified fish oil

Strength: 30g per 1000ml

Refined olive oil

Strength: 50g per 1000ml

Detailed Information

Contraindications

**Contraindications** - Hypersensitivity to fish-, egg-, soya or peanut protein or to any of the active substances or excipients. - Severe hyperlipidemia. - Severe liver insufficiency. - Severe blood coagulation disorders. - Severe renal insufficiency without access to hemofiltration or dialysis. - Acute shock. - General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, decompensated cardiac insufficiency. - Unstable conditions (e.g. severe post-traumatic conditions, uncompensated diabetes mellitus, acute myocardial infarction, stroke, embolism, metabolic acidosis and severe sepsis and hypotonic dehydration).

Indication Information

**Indications** Supply of energy and essential fatty acids and omega-3 fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

© Copyright 2025. All Rights Reserved by MedPath